17:50 , Nov 2, 2017 |  BC Innovations  |  Product R&D

Sweet specificity

Siamab Therapeutics Inc. is gearing up to compete in the small but active space of companies targeting sugar groups that are up-regulated in cancer. So far, its technology has produced a lead therapeutic, a deal...
19:55 , Jun 9, 2017 |  BC Week In Review  |  Clinical News

MabVax reports Phase Ia data for MVT-5873 in pancreatic cancer

MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported data from 32 evaluable patients with locally advanced or metastatic pancreatic cancer in an open-label, dose-escalation, U.S. Phase Ia trial showing that IV MVT-5873 (5B1 antibody, HuMab-5B1) led to...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

5B1 antibody: Phase I started

MabVax began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate 3 mg IV MVT-2163 with or without 17 or 47 mg IV MVT-5873 in about 28 patients. MabVax’s MVT-2163 is a radiolabeled HuMab-5B1...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

MVT-2163: Phase I started

MabVax began an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate 3 mg IV MVT-2163 with or without 17 or 47 mg IV MVT-5873 in about 28 patients. MabVax’s MVT-5873 is a human IgG1...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Clinical News

5B1 antibody: Phase I start

This month, MabVax will start an open-label, dose-escalation, dose-expansion, U.S. Phase I trial to evaluate HuMab-5B1 alone or with chemotherapy in up to 60 patients. MabVax Therapeutics Holdings Inc. (OTCQB:MBVX), San Diego, Calif.   Product:...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Company News

MabVax Therapeutics, Rockefeller University deal

MabVax and the university’s laboratory of molecular genetics and immunology partnered to optimize MabVax’s HuMab 5B1 Fc receptor-mediated antibody function and explore the mechanism of Fc variants of HuMab 5B1 in tumor clearance. MabVax will...